MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, has just formed a strategic alliance with Dasa, the largest medical diagnostics company in Latin America, to expand Brazilian patients' access to next-generation genomics and promote significant advancements in Brazil's healthcare sector.

Switzerland's Saphetor said Wednesday that it has received CE marking for VarSome Clinical, its genome interpretation platform.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Element Biosciences said Thursday that it has raised more than $277 million in Series D funding.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada. The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.

Oxford Nanopore Technologies has launched a new Pharmacogenomics (PGx) Beta Program with Twist Biosciences.

A team led by researchers at the University of Michigan has developed and clinically validated an 18-gene urinary test for detecting high-grade prostate cancer.

The House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party said on Thursday that it has introduced a new bill to ban the use of federal funding on "foreign adversary biotech companies," including China's BGI Group.

New research suggests a combination of molecular profiling on tumor tissue and corresponding circulating tumor DNA (ctDNA) samples can provide clinically actionable clues that may be missed using either approach alone, particularly for individuals with breast cancer or non-small cell lung cancer (NSCLC).

Chinese molecular diagnostic firm Dinfectome said on Monday that its DIFSeq-200 sequencer has obtained approval from the Chinese National Medical Products Administration (NMPA).